Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verdiperstat in Multiple System Atrophy
NCT02388295Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of verdiperstat in multiple system atrophy (MSA) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in Microglia Activation Via Positron Emission Tomography (PET) in Striatum Brain Region at 12 weeks. Started Apr 2015; status: completed.
02
Drugs
verdiperstat
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT02388295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388295.